公开(公告)号：US20240141356A1

公开(公告)日：2024-05-02

申请号：US18466254

申请日：2023-09-13

Applicant: The Hong Kong University of Science and Technology

Inventor： Kai LIU ,  Xu WANG ,  Chao YANG

IPC: C12N15/113 ,  A61K31/166 ,  A61K31/433 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0793 ,  C12N9/22

CPC classification number: C12N15/1137 ,  A61K31/166 ,  A61K31/433 ,  A61K45/06 ,  A61P25/00 ,  C12N5/0619 ,  C12N9/22 ,  C12N2310/122 ,  C12N2310/20

Abstract: The subject invention pertains to a method for promoting axon regeneration in a subject with central nervous system injury. More specifically, the method comprises activating STAT1 signaling, cGAS-STING pathway, or a combination thereof by administering IFNγ and inhibiting the expression or function Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2) inhibitor; or administering a STING agonist.

公开(公告)号：US20240132823A1

公开(公告)日：2024-04-25

申请号：US17769549

申请日：2020-10-11

Applicant: Wisconsin Alumni Research Foundation

Inventor： Zhenqiang Ma ,  Inkyu Lee ,  Juhwan Lee ,  Michael Phillips ,  David Gamm ,  Shaoqin Gong

IPC: C12M1/12 ,  C12N5/0793

CPC classification number: C12M25/14 ,  C12N5/062 ,  C12N2533/30

Abstract: Photoreceptor scaffolds that can be used for transplantation of organized photoreceptor tissue, with or without retinal pigment epithelial cells, which may improve grafted cell survival, integration, and functional visual rescue are disclosed herein. The scaffolds include a cell support layer having at least one honeycomb-shaped reservoir fluidly connected to a plurality of through-holes and at least one cell in the at least one honeycomb-shaped reservoir.

公开(公告)号：US20240131077A1

公开(公告)日：2024-04-25

申请号：US18472176

申请日：2023-09-20

Applicant: Astellas Institute for Regenerative Medicine

Inventor： Irina Klimanskaya ,  Robert P. Lanza

IPC: A61K35/30 ,  A61K9/00 ,  A61K35/44 ,  C12N5/079 ,  C12N5/0793

CPC classification number: A61K35/30 ,  A61K9/0048 ,  A61K35/44 ,  C12N5/062 ,  C12N5/0621 ,  A61K35/12 ,  C12N2501/01

Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

公开(公告)号：US20240124836A1

公开(公告)日：2024-04-18

申请号：US18391763

申请日：2023-12-21

Applicant: KEIO UNIVERSITY

Inventor： Minoru Ko

IPC: C12N5/0793 ,  C12N5/071 ,  C12N5/0735 ,  C12N5/0797 ,  C12N5/16

CPC classification number: C12N5/0619 ,  C12N5/0606 ,  C12N5/0623 ,  C12N5/067 ,  C12N5/0672 ,  C12N5/16 ,  C12N2501/60 ,  C12N2501/65 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2510/00

Abstract: Provided is a method of differentiating a pluripotent stem cell of mammalian origin into a desired cell type by predicting the direction of cell differentiation to be caused by induction of expression of a transcription factor. A human gene expression correlation matrix using human cells has been newly created, and further, it has been confirmed that human pluripotent stem cells can be differentiated into a desired cell type by introducing, into the human pluripotent stem cells, a transcription factor cocktail selected from the matrix.

公开(公告)号：US11957719B2

公开(公告)日：2024-04-16

申请号：US16823841

申请日：2020-03-19

Applicant: THE SCHEPENS EYE RESEARCH INSTITUTE

Inventor： Michael J. Young ,  Petr Y. Baranov

IPC: A61K35/30 ,  C12N5/079 ,  C12N5/0793 ,  G01N33/569

CPC classification number: A61K35/30 ,  C12N5/062 ,  C12N5/0621 ,  G01N33/56966 ,  G01N2333/46

Abstract: The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques.

公开(公告)号：US20240085402A1

公开(公告)日：2024-03-14

申请号：US18491513

申请日：2023-10-20

Applicant: Hoffmann-La Roche Inc.

Inventor： Veronica COSTA ,  Maj HEDTJÄRN ,  Marius HOENER ,  Ravi JAGASIA ,  Mads Aaboe JENSEN ,  Christoph PATSCH ,  Lykke PEDERSEN ,  Søren Vestergaard RASMUSSEN

IPC: G01N33/50 ,  C12N5/00 ,  C12N5/074 ,  C12N5/0793 ,  C12N5/0797 ,  C12N15/11 ,  C12N15/113

CPC classification number: G01N33/5014 ,  C12N5/0018 ,  C12N5/0619 ,  C12N5/0623 ,  C12N5/0696 ,  C12N15/11 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1137 ,  G01N33/5058 ,  C12N2310/11 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3231 ,  C12N2310/33 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2320/34 ,  C12N2500/38 ,  C12N2500/44 ,  C12N2501/01 ,  C12N2501/11 ,  C12N2501/115 ,  C12N2501/119 ,  C12N2501/13 ,  C12N2501/41 ,  C12N2501/60 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/45 ,  C12N2533/52

Abstract: The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

公开(公告)号：US20240076630A1

公开(公告)日：2024-03-07

申请号：US18231190

申请日：2023-08-07

Applicant: President and Fellows of Harvard College

Inventor： Giorgia Quadrato ,  Paola Arlotta

IPC: C12N5/071 ,  C12N5/079 ,  C12N5/0793

CPC classification number: C12N5/0697 ,  C12N5/0618 ,  C12N5/0619 ,  C12N5/0622 ,  C12N2501/115 ,  C12N2501/13 ,  C12N2503/04 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2513/00 ,  C12N2533/90

Abstract: Disclosed herein are 3-D neural tissue structures or “brain organoids” created from human pluripotent cells (e.g., stem cells) differentiated into neuronal cell types that include cortical and subcortical neuronal subtypes along with sensory cells. Also disclosed herein are methods for the in vitro generation of 3-D neural tissue structures capable of sensory perception, methods for generating a “brain organoid-machine interface” (BOMI), and methods for screening of molecular, cellular and network-level defects associated with complex mental diseases through use of patient-derived induced pluripotent stem cells.

公开(公告)号：US20240052306A1

公开(公告)日：2024-02-15

申请号：US18449971

申请日：2023-08-15

Applicant: The McLean Hospital Corporation

Inventor： Sangmi Chung

IPC: C12N5/0793 ,  A61K35/30

CPC classification number: C12N5/0619 ,  A61K35/30 ,  C12N2501/119 ,  C12N2501/13 ,  C12N2501/155 ,  C12N2501/41 ,  C12N2501/415 ,  C12N2506/02 ,  C12N2506/45 ,  C12N2501/115 ,  C12N2506/08

Abstract: Enhanced methods for the generation of medial ganglionic eminence (MGE) cells from pluripotent stem cells are provided that involve an additional step of contacting the cells with an activator of FGF8 signaling while differentiating Pax6+ cells progenitor cells into MGE cells with an activator of sonic hedgehog, and optionally a Wnt inhibitor. The activator of FGF8 signaling shifts the differentiation of the population of cells to NKX2.1+MGE cells, rather than to CopuTFII+ caudal ganglionic eminence (CGE) cells. Methods for treatment of neurological disorders, such as epilepsy, by transplant of MGE cells, or GABAergic interneurons derived from human pluripotent stem cells, into a subject in need of treatment are also provided. Human pluripotent stem cell derived MGE cells when transplanted successfully suppress spontaneous seizures, e.g. in epilepsy. We also have developed a method to purify MGE cells and maturing interneurons from differentiated pluripotent stem cells using cell surface marker and molecular beacon technology.

公开(公告)号：US11898164B2

公开(公告)日：2024-02-13

申请号：US16474662

申请日：2017-12-20

Applicant: JEIL PHARMACEUTICAL CO., LTD.

Inventor： Myung Soo Cho ,  Mi Sun Lim ,  So Yeon Ji

IPC: C12N5/00 ,  C12N5/0793 ,  C12N5/0797

CPC classification number: C12N5/0619 ,  C12N5/0623 ,  C12N2501/115 ,  C12N2506/08 ,  C12N2506/45 ,  C12N2533/20 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2533/90

Abstract: Disclosed is a method for producing a spherical neural mass having suppressed teratoma formation. When using the spherical neural mass produced according to the method of the present disclosure, the purity of the neuronal progenitor cells may be improved, the teratoma formation may be suppressed, and the viability and recovery percentage of the cell may be increased.

公开(公告)号：US20240034994A1

公开(公告)日：2024-02-01

申请号：US18258707

申请日：2021-12-24

Applicant: KYOTO UNIVERSITY ,  SATAKE MultiMix Corporation

Inventor： Haruhisa INOUE ,  Keiko IMAMURA ,  Takayuki KONDO ,  Ngoc Anh Suong DANG ,  Yoshikazu KATO

IPC: C12N5/0793

CPC classification number: C12N5/0619 ,  C12N2506/45 ,  C12N2501/385

Abstract: A cultured spherical body that is capable of easily performing quantitative analysis of a region containing brain neurons, useful as a supply source of neurons for transplantation, and can be used suitably for drug discovery screening for neurological diseases and compound evaluation systems is obtained. Provided are a cultured spherical body including a first cell layer containing neural stem cells and/or neural progenitor cells and a second cell layer containing brain neurons, wherein the first cell layer is present in the superficial portion of the cultured spherical body, and a method for producing the cultured spherical body.